Hers Review: One of the Biggest Names in Telehealth — And the Subject of an FTC Lawsuit Filed Nine Days Ago

What Is Hers?

Hers is the women's brand of Hims & Hers Inc., of 2269 Chestnut Street, San Francisco. The BBB records the business as starting on 30 December 2013 and incorporating in July 2017, rates it A+, and has accredited it since 22 February 2018. It is a publicly traded company and one of the largest direct-to-consumer telehealth operations in the United States, offering weight management, mental health, hair loss, skincare, sexual health and hormone care.

For a site with 'therapist' in its name, the mental health service is the most relevant part of the offering — Hers prescribes antidepressants and anxiety medication alongside its other lines. That also makes one of the FTC's allegations land harder than it otherwise would, and we return to it below.

We could not verify pricing at source: forhers.com returns a 403 to automated requests. The figures throughout this review come from secondary reporting and are labelled as reported rather than confirmed. As reported, Hers uses a two-part structure — a clinical membership at $39 for the first month and $149 a month thereafter, with medication charged separately on top. Compounded semaglutide is reported from $99 a month on a six-month plan paid upfront, oral compounded semaglutide from $49, brand-name Wegovy at $149 for the pill and $199 for the pen, and Zepbound at $299.

That membership figure matters. At $149 a month it is $1,788 a year before a single prescription, which is a different proposition from the medication prices in isolation.

The company's compounded GLP-1 business has also been through a turbulent eighteen months, and understanding that history explains why what Hers offers today is not what it offered in 2024.

Services & Reported Pricing

Every figure above is reported rather than verified, because forhers.com blocks automated access and we do not publish prices we cannot check. Two structural points survive that caveat. First, the membership and the medication are separate charges — a $99 compounded semaglutide plan sits on top of a $149 monthly membership, so the real monthly cost is closer to $250 than $99. Second, the brand-name prices are genuinely competitive: Wegovy at $149 for the pill and $199 for the pen, and Zepbound at $299, are far below the $900 to $1,399 we have documented elsewhere, reflecting manufacturer direct-pay programmes. If you want FDA-approved medication, that part of the offer is strong — provided you factor the membership in.

The Compounding History — and Why Today Isn't 2024

The compounded GLP-1 story here is the most consequential in this market and worth setting out in order, because it explains why Hers today is not what it was.

Hims & Hers began selling compounded semaglutide in May 2024, using the provision that allows compounding pharmacies to prepare copies of drugs on the FDA's shortage list. In **February 2025 the FDA declared the semaglutide shortage resolved**, which closed that route, with a grace period allowing 503A compounders until 22 April 2025 to stop.

In April 2025 Novo Nordisk partnered with Hims & Hers to sell genuine Wegovy through CenterWell Pharmacy. In **June 2025 Novo terminated that partnership**, publicly accusing the company of illegally mass compounding under what it called the false guise of personalisation, and of 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy'. Hims & Hers shares fell roughly 30%. Novo subsequently sued Hims for patent infringement over GLP-1 products.

The 'personalisation' point is the crux and is genuinely contested. Compounders argue that a personalised dose or a combination formulation — semaglutide with vitamin B12, say, or a non-standard strength — falls within the exemption for compounding tailored to an individual patient, even after a shortage ends. The FDA has pushed back on that reading. It is unresolved law, and a buyer should understand they are purchasing into an unsettled area rather than a clearly permitted one.

As reported, Hers changed course in March 2026, moving toward FDA-approved medication and limiting compounded semaglutide to cases of medical necessity, with availability not guaranteed. If you are choosing Hers specifically for compounded semaglutide, confirm you can actually get it before paying a membership fee.

One further point on the compounded oral products, reported from $49 a month. Semaglutide is a peptide destroyed by digestion, which is why the only FDA-approved oral version uses a specific absorption enhancer and strict dosing conditions. Compounded oral semaglutide is not that product and its absorption has not been established. Ask directly what evidence exists that the dose reaches your bloodstream.

The oral medication kits combining metformin, bupropion, topiramate, naltrexone and vitamin B12 also deserve scrutiny. Bupropion plus naltrexone is essentially the composition of Contrave, and topiramate features in Qsymia — both FDA-approved combination products that have been through review as combinations. Compounding those ingredients instead means the specific combination has not. Each carries real risk: bupropion lowers the seizure threshold, naltrexone blocks opioid analgesia and can precipitate withdrawal, and topiramate causes cognitive slowing and is teratogenic.

The Consultation Process

Eligibility

• •Adults, across all 50 states, following an online intake. Hers serves women specifically, though the underlying company also operates Hims.
• •GLP-1 medicines are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy or while trying to conceive. For a service aimed at women, that last point deserves particular attention — discuss contraception with the prescriber if there is any possibility of pregnancy.
• •Clinician judgement is required for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or diabetic retinopathy.
• •Common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and reflux — usually worst after a dose increase. Less common but serious risks include pancreatitis, gallbladder disease and dehydration-related kidney injury.
• •The oral kits carry their own profile. Bupropion lowers the seizure threshold and is contraindicated in seizure disorders and in eating disorder history — relevant given the population. Naltrexone must not be taken by anyone using opioids and will block opioid pain relief if you are injured. Topiramate causes cognitive slowing and tingling, and is teratogenic, so it must not be used in pregnancy.
• •Rapid weight loss costs lean muscle as well as fat, and can trigger telogen effluvium — diffuse hair shedding — which is a recognised issue with GLP-1 treatment and usually self-limiting.
• •If you are using the mental health service, tell the prescriber about every other medication you take, including anything from the weight-loss side. Bupropion in particular interacts with several antidepressants.

Clinicians, Labs & Pharmacy

Shipping & Support Services

Medication ships directly to patients. Shipping terms were not verifiable at source.

• •One of the largest telehealth platforms in the US, operating in all 50 states
• •Trading since December 2013; BBB accredited since February 2018 with an A+ rating
• •Genuinely broad service range — weight, mental health, hair, skin, sexual health, hormones
• •Brand-name pricing is competitive: Wegovy reported at $149 (pill) and $199 (pen), Zepbound at $299
• •Moved toward FDA-approved medication in March 2026 rather than continuing to lean on compounding
• •Publicly traded, with the disclosure obligations that brings
• •Established pharmacy and fulfilment infrastructure at scale
• •Mental health prescribing available alongside physical health services

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Hers May Be Best For

• •People who want brand-name Wegovy or Zepbound and have factored the membership into the total
• •Anyone who wants weight, mental health and hormone care from a single large provider
• •Buyers who will screenshot the checkout, locate the cancellation path immediately and diarise renewals
• •Those comfortable proceeding while an FTC case about billing and privacy is pending

Limitations

• •The FTC lawsuit is the finding, it is nine days old, and it goes to precisely the things this site tells readers to check. Filed on 29 July 2026 in the US District Court for the Northern District of California, joined by California and Utah, on a 2-0 Commission vote, it alleges that Hims 'fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider'; that 'Hims does not give most consumers a consultation with a provider'; that consumers are therefore 'unknowingly… charged for and subscribed to a prescription treatment without having a chance to review or approve it'; and that the cancellation button 'appeared only after these consumers selected an option to add/remove items from order and navigated several steps before they even saw the word cancel'. Hims denies wrongdoing, and the FTC's own notice is explicit that it files when it has 'reason to believe' the law is being violated and that 'the case will be decided by the court'. Nothing is proven. But a buyer is entitled to weigh it.
• •The privacy allegation deserves separate emphasis on a mental health site. The complaint alleges Hims 'shared consumers' sensitive health information with third-party advertising platforms such as Meta and Snap despite promising to protect patient privacy' — both by sharing customer lists directly and through tracking technologies that automatically transmitted 'Events' from the website. For someone using a service for hair loss, that is a serious breach of trust. For someone using it for depression or anxiety, it is considerably worse, because the fact of seeking treatment is itself the sensitive information. If you are considering Hers for mental health specifically, that allegation is the one to weigh hardest.
• •The BBB record corroborates the billing theme from an independent direction. Its profile — which rates the company A+ and has accredited it since 2018 — notes that 'complaints on file concern issues with cancelling orders and refund requests', and quotes the company's refund terms as making payments 'final, irrevocable and not subject to refund'. An A+ accredited rating alongside that observation tells you the company engages with the BBB; it does not tell you the billing experience is good.
• •On price, the two-part structure is the thing most likely to catch people out. A reported $99 compounded semaglutide plan is not $99 a month — it sits on top of a $149 monthly membership, so the realistic figure is around $250. The brand-name prices are genuinely good in isolation, and if you want FDA-approved medication Wegovy at a reported $149 to $199 is competitive; just do the addition first.
• •Finally, the compounding history is worth carrying into any decision. The FDA declared the semaglutide shortage resolved in February 2025; Novo Nordisk partnered with Hims in April 2025 and terminated in June, publicly alleging deceptive promotion of 'illegitimate, knockoff versions of Wegovy', then sued over patents. Hers has reportedly since narrowed compounded semaglutide to medical necessity. None of that makes today's service unlawful, but it means the compounded route here sits in genuinely unsettled territory — and if compounded semaglutide is why you are signing up, confirm you can actually get it before paying a membership fee.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Hers is one of the largest telehealth brands in America, trading since 2013, BBB accredited since 2018 with an A+ rating, operating in all fifty states across weight management, mental health, hair, skin, sexual health and hormones. Its brand-name GLP-1 pricing is genuinely competitive at a reported $149 to $299, and it moved toward FDA-approved medication in March 2026 rather than continuing to lean on compounding. On scale and range, few competitors come close.

Nine days before this review, the Federal Trade Commission, California and Utah sued it in federal court. The complaint alleges that consumers are charged for prescriptions almost immediately after submitting an intake form despite being told they will consult a provider first; that most never receive that consultation and are 'unknowingly… charged for and subscribed to a prescription treatment without having a chance to review or approve it'; that the cancellation button appeared 'only after these consumers selected an option to add/remove items from order and navigated several steps before they even saw the word cancel'; and that the company shared health data with Meta and Snap while promising privacy. Hims denies all of it, and the FTC states plainly that a court will decide.

We are not treating allegations as findings. But this site exists to tell readers what to check before handing over a card, and a federal regulator has now alleged — after a roughly three-year investigation — that the four things most worth checking are exactly where this company falls short. The BBB, which rates it A+, independently notes that 'complaints on file concern issues with cancelling orders and refund requests'.

The privacy allegation is the one we would weigh hardest, and specifically on a mental health site. Sharing that someone sought treatment for depression with an advertising platform is not the same order of harm as sharing that they bought shampoo, and it cannot be undone.

On cost, the structure matters more than the headline. A reported $149 monthly membership sits on top of medication, so a $99 plan is really about $250 a month and $1,788 a year before a single prescription. And the refund terms are quoted as making payments 'final, irrevocable'.

We rate Hers 2.8 out of 5 — a large, capable, well-resourced company facing an active federal case about the precise consumer protections that matter most here.

If you want brand-name medication, the pricing is good and competitors like AgelessRx and PlushCare offer comparable products without a pending FTC action. If you sign up here anyway, screenshot the checkout, get your total cost in writing, find the cancel button on day one, and diarise your own refill date.

This review is informational only and is not medical advice. Compounded semaglutide is not FDA-approved. Speak to a licensed clinician before starting, changing or stopping any medication.